What Is the Treatment of Tumor Lysis Syndrome in Low-Risk Patients?

Not all patients facing tumour lysis syndrome require the same intensity of intervention. In those assessed as low risk, a targeted preventive strategy — begun before treatment starts — is the standard of care. Even at low risk, the window before the first cycle of therapy is the critical time to act.

Clinical Scenario

This protocol is for patients classified as having a low risk of tumour lysis syndrome. Risk stratification drives the choice of prophylactic measures, and low-risk patients have a defined, guideline-supported approach distinct from intermediate- or high-risk management.

Management Approach — Overview

The strategy centres on adequate oral hydration initiated before therapy begins, combined with a xanthine oxidase inhibitor started in advance of the first treatment cycle. An alternative agent from the same class is available for patients who cannot tolerate the first-line option. The complete regimen — including timing, durations, dosing by patient type, and decision points — is in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/bjh.70092

Patients with low risk of TLS: consider allopurinol for the first 7 days of the first cycle of treatment (2C).

Allopurinol can be considered in those with low or intermediate risk of TLS.

This should be started at least 12 h prior to definitive therapy.

Patients should be encouraged to drink 2–3 L fluid (children: 2–3 L/m2/day) the day before, the day of and the day after initiation of a new line of therapy.

An alternative xanthine oxidase inhibitor with fewer interactions is febuxostat 120 mg daily for adults.

View source ↗